90 related articles for article (PubMed ID: 25319731)
1. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Berg T; Andreone P; Pol S; Roberts S; Younossi Z; Diago M; Lawitz EJ; Focaccia R; Foster GR; Horban A; Lonjon-Domanec I; DeMasi R; Picchio G; Luo D; De Meyer S; Zeuzem S
Liver Int; 2015 Feb; 35(2):448-54. PubMed ID: 25319731
[TBL] [Abstract][Full Text] [Related]
2. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
7. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM; Alonso S; Martinez SM; Forns X; Sanchez-Tapias JM; Rincón D; Rodriguez-Caravaca G; Bárcena R; Serra MA; Romero-Gómez M; Fernandez I; Garcia-Samaniego J; Fuente J; Solá R; Moreno-Otero R; Planas R;
Am J Gastroenterol; 2010 Oct; 105(10):2164-72; quiz 2173. PubMed ID: 20700116
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Foster GR; Hézode C; Bronowicki JP; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
Gastroenterology; 2011 Sep; 141(3):881-889.e1. PubMed ID: 21699786
[TBL] [Abstract][Full Text] [Related]
11. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
Foster GR; Zeuzem S; Andreone P; Pol S; Lawitz EJ; Diago M; Roberts S; Pockros PJ; Younossi Z; Lonjon-Domanec I; De Meyer S; Luo D; George S; Beumont M; Picchio G
J Hepatol; 2013 Mar; 58(3):488-94. PubMed ID: 23183521
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
Alavian SM; Tabatabaei SV; Keshvari M; Behnava B; Miri SM; Elizee PK; Lankarani KB
Liver Int; 2010 Sep; 30(8):1173-80. PubMed ID: 20629950
[TBL] [Abstract][Full Text] [Related]
15. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Nakamuta M; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
Antiviral Res; 2014 Apr; 104():102-9. PubMed ID: 24462955
[TBL] [Abstract][Full Text] [Related]
16. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
18. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
Cesari M; Caramma I; Antinori S; Adorni F; Galli M; Milazzo L
HIV Med; 2009 Oct; 10(9):580-5. PubMed ID: 19785667
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]